Baxter BioScience, Merrimack seek European approval for pancreatic cancer treatment MM-398
The submission follows Merrimack’s recent filing of a new drug application (NDA) for this indication with the United States Food and Drug Administration (FDA). "Our coordinated U.S. and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.